Clinical features of hepatocellular carcinoma in patients with autoimmune hepatitis in Japan

Journal of Gastroenterology

Volumn 48, Issue 1, 2013, Pages 109-114

  Ohira, Hiromasa ^a   Abe, Kazumichi ^a   Takahashi, Atsushi ^a   Zeniya, Mikio ^b   Ichida, Takafumi ^c  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c JUNTENDO UNIVERSITY   (Japan)

Author keywords

Autoimmune hepatitis; Cirrhosis; Diabetes mellitus; Hepatocellular carcinoma; Liver Cancer Study Group of Japan

Indexed keywords

AZATHIOPRINE; SORAFENIB; STEROID;

ADULT; AGED; ARTICLE; AUTOIMMUNE HEPATITIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHILD PUGH SCORE; CLINICAL FEATURE; DRUG EFFECT; FEMALE; HEALTH SURVEY; HUMAN; JAPAN; JAPANESE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTON THERAPY; RADIOFREQUENCY ABLATION; SEX RATIO; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ALPHA-FETOPROTEINS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; HEPATECTOMY; HEPATITIS, AUTOIMMUNE; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PLATELET COUNT; PROTEIN PRECURSORS; PROTHROMBIN; SURVIVAL RATE;

EID: 84872495501     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-012-0616-x     Document Type: Article

References (24)

1. Park SZ, Nagorney DM, Czaja AJ. Hepatocellular carcinoma in autoimmune hepatitis. Dig Dis Sci. 2000;45:1944-8.
2. Wang KK, Czaja AJ. Hepatocellular carcinoma in corticosteroid-treated severe autoimmune chronic active hepatitis. Hepatology. 1988;8:1679-83.
3. Miyake Y, Sakaguchi K, Tanaka H, et al. Development of hepatocellular carcinoma in a woman with HBV- and HCV-negative autoimmune hepatitis with unsatisfactory response to corticosteroid. Intern Med. 2005;44:949-53.
4. Yamamoto K, Hiura M, Tabaru A, et al. Rapid progression of hepatocellular carcinoma in a patient with autoimmune hepatitis. Intern Med. 2011;50:1409-13.
5. Teufel A, Weinmann A, Centner C, et al. Hepatocellular carcinoma in patients with autoimmune hepatitis. World J Gastroenterol. 2009;15:578-82.
6. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual. 7th ed. New York: Springer; 2010. p. 237-46.
7. Abe M, Mashiba T, Zeniya M, Yamamoto K, Onji M. Present status of autoimmune hepatitis in Japan: a nationwide survey. J Gastroenterol. 2011;46:1136-41.
8. Toda G, Zeniya M, Watanabe F, et al. Present status of autoimmune hepatitis in Japan-correlating the characteristics with international criteria in an area with a high rate of HCV infection. J Hepatol. 1997;26:1207-12.
9. Montano-Loza AJ, Carpenter HA, Czaja AJ, et al. Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis. Am J Gastroenterol. 2008;103:1944-51.
10. Yeoman AD, Al-Chalabi T, Karani JB, et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: implications for follow-up and screening. Hepatology. 2008;48:863-70.
11. Dragani TA. Risk of HCC: genetic heterogeneity and complex genetics. J Hepatol. 2010;52:252-7.
12. Trivedi PJ, Cullen S. Autoimmune hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). Dig Dis Sci. 2011;56:276-8.
13. Wong RJ, Gish R, Frederick T, Bzowej N, Frenette C. Development of hepatocellular carcinoma in autoimmune hepatitis patients: a case series. Dig Dis Sci. 2011;56:578-85.
14. Migita K, Watanabe Y, Jiuchi Y, Nakamura Y, Saito A, Yagura M. et al. Evaluation of risk factors for the development of cirrhosis in autoimmune hepatitis: Japanese NHO-AIH prospective study. J Gastroenterol. 2011;46 Suppl 1:56-62.
15. Blonski W, Kotlyar DS, Forde KA. Non-viral causes of hepatocellular carcinoma. World J Gastroenterol. 2010;16:3603-15.
16. Samarasena J, Borgaonkar M. Development of hepatocellular carcinoma in a patient with Crohn's disease treated with azathioprine. Dig Dis Sci. 2007;52:2748-50.
17. Ishida M, Naka S, Shiomi H, et al. Hepatocellular carcinoma occurring in a Crohn's disease patient. World J Gastroenterol. 2010;16:3215-8.
18. Hino-Arinaga T, Ide T, Kuromatsu R, et al. Risk factor for hepatocellular carcinoma in Japanese patients with autoimmune hepatitis type 1. J Gastroenterol. 2011.
19. Wong DK, Huang FY, Lai CL, et al. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology. 2011;54:829-36.
20. Watanabe T, Soga K, Hirono H, et al. Features of hepatocellular carcinoma in cases with autoimmune hepatitis and primary biliary cirrhosis. World J Gastroenterol. 2009;15:231-9.
21. Macaron C, Hanouneh IA, Zein NN. Incidence and risk factors of hepatocellular carcinoma in patients with primary biliary cirrhosis. Hepatology. 2010;52:2239-40.
22. Liver Cancer Study Group of Japan. Survey and follow-up study of primary liver cancer in Japan. Report 18 (2004-2005). Kanzo. 2010;51:460-84.
23. Ikai I, Arii S, Okazaki M, et al. Report of the 17th nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res. 2007;37:676-91.
24. Kudo M. Real practice of hepatocellular carcinoma in Japan: conclusions of the Japan Society of Hepatology 2009 Kobe Congress. Oncology. 2010;78:180-8.